Fig. 4

Subgroup analysis of OS and RFS between postoperative adjuvant TACE and conservation. a The OS of HCC patients with MVI in three various types of pa-TACE treatment; b case number (> 100, < 100), overall survival; c follow-up time (> 5 years, ≤ 5 years), overall survival; d The RFS of HCC patients with MVI in three various types of pa-TACE treatment; e case number (> 100, < 100), RFS; f follow-up time (> 5 years, ≤ 5 years), RFS